163 related articles for article (PubMed ID: 19652624)
1. Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.
Stinchcombe TE; Hodgson L; Herndon JE; Kelley MJ; Cicchetti MG; Ramnath N; Niell HB; Atkins JN; Akerley W; Green MR; Vokes EE;
J Thorac Oncol; 2009 Sep; 4(9):1117-25. PubMed ID: 19652624
[TBL] [Abstract][Full Text] [Related]
2. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.
Socinski MA; Zhang C; Herndon JE; Dillman RO; Clamon G; Vokes E; Akerley W; Crawford J; Perry MC; Seagren SL; Green MR
Ann Oncol; 2004 Jul; 15(7):1033-41. PubMed ID: 15205196
[TBL] [Abstract][Full Text] [Related]
3. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
4. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.
Pöttgen C; Gauler T; Bellendorf A; Guberina M; Bockisch A; Schwenzer N; Heinzelmann F; Cordes S; Schuler MH; Welter S; Stamatis G; Friedel G; Darwiche K; Jöckel KH; Eberhardt W; Stuschke M
J Clin Oncol; 2016 Jul; 34(21):2526-33. PubMed ID: 27247220
[TBL] [Abstract][Full Text] [Related]
5. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
7. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
Fournel P; Vergnenégre A; Robinet G; Léna H; Gervais R; Le Caer H; Souquet PJ; Chavaillon JM; Bozonnat MC; Daurès JP; Chouaid C; Martel-Lafay I;
Eur J Cancer; 2016 Jan; 52():181-7. PubMed ID: 26689864
[TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
Vokes EE; Herndon JE; Kelley MJ; Cicchetti MG; Ramnath N; Neill H; Atkins JN; Watson DM; Akerley W; Green MR;
J Clin Oncol; 2007 May; 25(13):1698-704. PubMed ID: 17404369
[TBL] [Abstract][Full Text] [Related]
9. Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial.
Guberina M; Eberhardt W; Stuschke M; Gauler T; Heinzelmann F; Cheufou D; Kimmich M; Friedel G; Schmidberger H; Darwiche K; Jendrossek V; Schuler M; Stamatis G; Pöttgen C
Ann Oncol; 2017 May; 28(5):1084-1089. PubMed ID: 28453703
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer.
Arslan D; Tural D; Koca T; Tastekin D; Kaymak Cerkesli A; Basaran H; Gunduz S; Murat Tatli A; Sezgin Goksu S; Uysal M; Kargi A; Kargi B; Koral L; Ibrahim Bassorgun C; Unal D; Mutlu H; Senol Coskun H; Ozdogan M; Bozcuk H
J BUON; 2015; 20(2):573-9. PubMed ID: 26011352
[TBL] [Abstract][Full Text] [Related]
11. How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial.
Strøm HH; Bremnes RM; Sundstrøm SH; Helbekkmo N; Aasebø U
Clin Lung Cancer; 2015 May; 16(3):183-92. PubMed ID: 25481662
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
Guberina M; Eberhardt W; Stuschke M; Gauler T; Aigner C; Schuler M; Stamatis G; Theegarten D; Jentzen W; Herrmann K; Pöttgen C
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1439-1447. PubMed ID: 30710323
[TBL] [Abstract][Full Text] [Related]
14. Five-Year Survival Among Stage IIIA Lung Cancer Patients Receiving Two Different Treatment Modalities.
Bilfinger T; Keresztes R; Albano D; Nemesure B
Med Sci Monit; 2016 Jul; 22():2589-94. PubMed ID: 27442604
[TBL] [Abstract][Full Text] [Related]
15. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.
Stinchcombe TE; Morris DE; Moore DT; Bechtel JH; Halle JS; Mears A; Deschesne K; Rosenman JG; Socinski MA
Lung Cancer; 2006 Apr; 52(1):67-74. PubMed ID: 16499996
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment.
Bonomi P; Gale M; Rowland K; Taylor SG; Purl S; Reddy S; Lee MS; Phillips A; Kittle CF; Warren W
Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):247-52. PubMed ID: 1846847
[TBL] [Abstract][Full Text] [Related]
17. Important prognostic factors for the long-term survival in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy.
Crvenkova S; Pesevska M
J BUON; 2015; 20(3):775-81. PubMed ID: 26214630
[TBL] [Abstract][Full Text] [Related]
18. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
Katakami N; Tada H; Mitsudomi T; Kudoh S; Senba H; Matsui K; Saka H; Kurata T; Nishimura Y; Fukuoka M
Cancer; 2012 Dec; 118(24):6126-35. PubMed ID: 22674529
[TBL] [Abstract][Full Text] [Related]
19. Patterns of treatment and survival among older patients with stage III non-small cell lung cancer.
Driessen EJM; Schulkes KJG; Dingemans AC; van Loon JGM; Hamaker ME; Aarts MJ; Janssen-Heijnen MLG
Lung Cancer; 2018 Feb; 116():55-61. PubMed ID: 29413051
[TBL] [Abstract][Full Text] [Related]
20. Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer.
Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Mertsoylu H; Hahn SM
Lung Cancer; 2018 Jul; 121():30-36. PubMed ID: 29858023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
